Author

Riu Yamashita

h-index 8 View on Semantic Scholar

We have 3 of 47 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Landscape of cancer genomics and precision oncology in Japan, South Korea, China, and Australia

Summary Precision oncology has expanded rapidly across the Asia–Pacific region, yet implementation remains heterogeneous because of differences in health-system organisation, reimbursement, molecular tumour board infrastructure, workforce capacity, and data integration. This structured narrative review with expert cons...

H. Bando, H. Okayama, Yoon Jung Chang et al. · The Lancet Regional Health -... · 1 citation

Open access Sep 2026

Changes and clinical impact of HER3 and ERBB3 expression in primary and recurrent ovarian cancer.

OBJECTIVE Human epidermal growth factor receptor (HER) 3, encoded by the ERBB3 gene, transduces signals most effectively when dimerized with HER2. Although HER3 protein expression has been considered a poor prognostic factor in ovarian cancer, limited data exist on changes in HER3 protein expression and ERBB3 messenger...

K. Yokosu, Riu Yamashita, Satoshi Fujii et al. · Journal of Gynecologic Oncol... · 0 citations

Review Open access Jul 2026

AI-integrated multi-omics platform to revolutionize anti-metastatic therapy development through circulating tumor cell profiling: SCRUM-MONSTAR-CTC

It is proposed that the next phase of precision oncology should integrate the cellular dimension of metastasis through systematic circulating tumor cell (CTC) profiling and highlights adherent-to-suspension transition (AST) as one representative, experimentally tractable plasticity program that enables tumor cells to s...

T. Hashimoto, T. Shibuki, T. Fujisawa et al. · International Journal of Cli... · 0 citations